Evidence map›Paper›PMID 28416540›Full record

ArticleAntimicrobial agents and chemotherapy2017

Seyedmojtaba Seyedmousavi, Johan W Mouton, Willem J G Melchers, Paul E Verweij

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Resistance profiling ofEmerging microbes & infections · 2022
    Article
  2. Article
  3. Antimicrobial agents and chemotherapy · 2019
    Article
  4. Methodologies forMicrobial cell (Graz, Austria) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Seyedmojtaba SeyedmousaviDepartment of Medical Microbiology, Radboud University Medical Centre, Nijmegen, the Netherlands.ORCID 0000-0002-6194-7447
Johan W MoutonDepartment of Medical Microbiology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Willem J G MelchersDepartment of Medical Microbiology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Paul E VerweijDepartment of Medical Microbiology, Radboud University Medical Centre, Nijmegen, the Netherlands Paul.Verweij@radboudumc.nl.
Radboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Using an immunocompetent murine model of invasive aspergillosis (IA), we previously reported that the efficacy of liposomal amphotericin B (L-AmB) (Ambisome) is not hampered by the presence of azole resistance mutations in

Indexed as

Amphotericin BAspergillosisAspergillus fumigatusAzolesCortisoneCyclophosphamideDrug Resistance, FungalAmphotericin BAzolesCortisoneCyclophosphamideliposomal amphotericin BAspergillus fumigatuscortisonecyclophosphamideimmunocompetentimmunosuppressioninvasive aspergillosisliposomal amphotericin B

Identifiers

PMID28416540
PMCPMC5444178
OpenAlexW2605735479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.